In contrast, the TKI Lapatinib targeting both EGFR and HER2 did not improve clinical outcome in phase III studies for stage IV HER2+ gastric cancer patients in combination with standard chemotherapy compared to chemotherapy alone, in either first-line [20] or second-line [21] therapy. Here, EGFR is linked to gastric cancer.